Hydroxyurea Capsule IP 500mg (Tharolax) Taj Pharma
Hydroxyurea 500mg Capsule is used in the treatment of some kinds of cancer and to prevent painful episodes associated with sickle cell anemia. It may be also used to treat some other conditions. It is sometimes used with certain other medicines as part of combination chemotherapy.
Hydroxyurea 500mg Capsule can be taken with or without food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.
The most common side effects of this medicine include nausea, vomiting, diarrhea, loss of appetite and sore mouth. This medicine may reduce the number of blood cells in your blood thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells along with kidney, liver and heart function during treatment with this medicine.
Before taking it, tell your doctor if you have bleeding, liver, or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your doctor know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.
USES OF HYDROXYUREA CAPSULE
- Head and neck cancer
- Sickle cell anemia
SIDE EFFECTS OF HYDROXYUREA CAPSULE
- Increased bleeding tendency
- Low blood platelets
- Loss of appetite
- Upset stomach
HOW TO USE HYDROXYUREA CAPSULE
Take this medicine in the dose and duration as advised by your doctor. Do not chew, crush or break it. Hydroxyurea 500mg Capsule may be taken with or without food, but it is better to take it at a fixed time.
HOW HYDROXYUREA CAPSULE WORKS
In cancer, Hydroxyurea 500mg Capsule works by blocking an enzyme (ribonucleotide reductase) which is required for synthesis of DNA. This prevents the cancer cells from growing and multiplying. In sickle cell disease, it works by increasing fetal haemoglobin (HbF) levels in red blood cells (RBCs). This helps the RBCs assume a normal shape, improves blood flow and protects against complications such as painful sickle cell episodes.
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Hydroxyurea 500mg Capsule. Please consult your doctor.
CONSULT YOUR DOCTOR
Hydroxyurea 500mg Capsule is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
CONSULT YOUR DOCTOR
Hydroxyurea 500mg Capsule is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Hydroxyurea 500mg Capsule may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Hydroxyurea 500mg Capsule should be used with caution in patients with kidney disease. Dose adjustment of Hydroxyurea 500mg Capsule may be needed. Please consult your doctor.
Regular monitoring of kidney function test and some blood tests may be advised while you are taking this medicine.
Hydroxyurea 500mg Capsule should be used with caution in patients with liver disease. Dose adjustment of Hydroxyurea 500mg Capsule may be needed. Please consult your doctor.
Hydroxyurea Capsule IP 500mg (Tharolax) Taj Pharma
1. NAME OF THE MEDICINAL PRODUCT
Hydroxyurea Capsule IP 500mg Taj Pharma
2.QUALITATIVE AND QUANTITATIVE COMPOSITION??????????????????????????????
Each capsule contains:
Hydroxycarbamide IP?? 500mg
Lactose monohydrate?? 42.2mg???????????????
For the full list of excipients, see section 6.1.
Size 0 hard gelatin capsule with an opaque pink body and an opaque green cap, containing a white homogeneous powder.
4.1 Therapeutic indications
The treatment of chronic myeloid leukaemia.
The treatment of cancer of the cervix in conjunction with radiotherapy.
4.2 Posology and method of administration
Treatment regimens can be continuous or intermittent. The continuous regimen is particularly suitable for chronic myeloid leukaemia, while the intermittent regimen, with its diminished effect on the bone marrow, is more satisfactory for the management of cancer of the cervix.
Hydroxyurea capsule should be started 7 days before concurrent irradiation therapy. If Hydroxyurea capsule is used concomitantly with radiotherapy, adjustment of radiation dosage is not usually necessary.
An adequate trial period for determining the antineoplastic effect of Hydroxyurea capsule is six weeks. Where there is a significant clinical response therapy may be continued indefinitely, provided that the patient is kept under adequate observation and shows no unusual or severe reactions. Therapy should be interrupted if the white cell count drops below 2.5×109L or the platelet count below 100×109/L .
In these cases, the counts should be reevaluated after three days and therapy resumed when the counts return to acceptable levels. Hematopoietic rebound is usually rapid. If rapid rebound has not occurred during combined Hydroxyurea capsule and irradiation therapy, irradiation may also be interrupted. Anemia, even if severe, can be managed without interrupting Hydroxyurea capsule therapy.
Severe gastric distress, such as nausea, vomiting, and anorexia, resulting from combined therapy may usually be controlled by interruption of Hydroxyurea capsule administration.
Pain or discomfort from inflammation of the mucous membranes at the irradiated site (mucositis) is usually controlled by measures such as topical anesthetics and orally administered analgesics. If the reaction is severe, Hydroxyurea capsule therapy may be temporarily interrupted; if it is extremely severe, irradiation dosage may, in addition, be temporarily postponed.
Hydroxyurea capsule 20-30 mg/kg should be given daily in single doses. Dosage should be based on the patient’s actual or ideal weight, whichever is the less. Therapy should be monitored by repeat blood counts.
Hydroxyurea capsule 80 mg/kg in single doses should be given every third day. Using the intermittent regimes the likelihood of WBC depression is diminished, but if low counts are produced, 1 or more doses of Hydroxyurea capsule should be omitted.
Concurrent use of Hydroxyurea capsule with other myelosuppressive agents may require adjustments of dosages.
Because of the rarity of these conditions in children, dosage regimens have not been established.
Elderly patients may be more sensitive to the effects of hydroxycarbamide, and may require a lower dosage regimen.
Since renal excretion is a pathway of elimination, consideration should be given to decreasing the dosage of Hydroxyurea capsule in this population.
Method of administration
For oral use.
NB: If the patient prefers, or is unable to swallow capsules, the contents of the capsules may be emptied into a glass of water and taken immediately. The contents of capsules should not be inhaled or allowed to come into contact with the skin or mucous membranes. Spillages must be wiped immediately.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Marked leucopenia (<2.5wbcx109/L), thrombocytopenia (< 100×109/L), or severe anaemia.
4.4 Special warnings and precautions for use
The complete status of the blood, including bone marrow examination, if indicated, as well as kidney function and liver function should be determined prior to, and repeatedly during, treatment. If bone marrow function is depressed, treatment with Hydroxyurea capsule should not be initiated. The determination of haemoglobin level, total leukocyte counts, and platelet counts should be performed at least once a week throughout the course of hydroxycarbamide therapy. If WBC falls below 2.5×109/L or platelet count to <100×109/L, therapy should be interrupted. Counts should be rechecked after 3 days and treatment resumed when they rise significantly towards normal.
Hydroxyurea capsule may produce bone marrow suppression; leukopenia is generally its first and most common manifestation. Thrombocytopenia and anaemia occur less often and are seldom seen without a preceding leukopenia. Bone marrow depression is more likely in patients who have previously received radiotherapy or cytotoxic cancer chemotherapeutic agents; Hydroxyurea capsule should be used cautiously in such patients. The recovery from myelosuppression is rapid when Hydroxyurea capsule therapy is interrupted.
Severe anaemia must be corrected with whole blood replacement before initiating therapy with hydroxycarbamide. If, during treatment, anaemia occurs, correct without interrupting Hydroxyurea capsule therapy. Erythrocytic abnormalities; megaloblastic erythropoeisis, which is self-limiting, is often seen early in the course of hydroxycarbamide therapy. The morphologic change resembles pernicious anaemia, but is not related to vitamin B12?or folic acid deficiency. The macrocytosis may mask the incidental development of folic acid deficiency; regular determinations of serum folic acid are recommended. Hydroxycarbamide may also delay plasma iron clearance and reduce the rate of iron utilisation by erythrocytes but it does not appear to alter the red blood cell survival time.
Patients who have received irradiation therapy in the past may have an exacerbation of postirradiation erythema when Hydroxyurea capsule is given.
Hydroxycarbamide should be used with caution in patients with marked renal dysfunction.
Hydroxycarbamide is not licensed for use in combination with antiretroviral agents for HIV disease and it may cause treatment failure and toxicities (in some cases fatal) in HIV patients.
In patients receiving long-term therapy with hydroxycarbamide for myeloproliferative disorders, such as polycythemia, secondary leukaemia has been reported. It is unknown whether this leukaemogenic effect is secondary to hydroxycarbamide or associated with the patient’s underlying disease. Skin cancer has also been reported in patients receiving long-term hydroxycarbamide. Patients should be advised to protect skin from sun exposure, conduct self-inspection of the skin and be screened for secondary malignancies during routine follow-up visits.
Cutaneous vasculitic toxicities including vasculitic ulcerations and gangrene have occurred in patients with myeloproliferative disorders during therapy with hydroxycarbamide. The risk of vasculitic toxicities is increased in patients who receive prior or concomitant interferon therapy. The digital distribution of these vasculitic ulcerations and progressive clinical behaviour of peripheral vasculitic insufficiency leading to digital infarct or gangrene were distinctly different than the typical skin ulcers generally described with Hydroxycarbamide. Due to potentially severe clinical outcomes for the cutaneous vasculitic ulcers reported in patients with myeloproliferative disease, hydroxycarbamide should be discontinued if cutaneous vasculitic ulcerations develop and alternative cytoreductive agents should be initiated as indicated.
The possibility of an increase in serum uric acid, resulting in the development of gout or, at worst, uric acid nephropathy, should be borne in mind in patients treated with hydroxycarbamide, especially when used with other cytotoxic agents. It is therefore important to monitor uric acid levels regularly and maintain a high fluid intake during treatment.
This product contains lactose, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Concomitant use of Hydroxyurea capsule with a live virus vaccine may potentiate the replication of the vaccine virus and/or may increase some of the adverse reactions of the vaccine virus because normal defence mechanisms may be suppressed by hydroxycarbamide. Vaccination with a live vaccine in a patient taking Hydroxyurea capsule may result in severe infection. The patient’s antibody response to vaccines may be decreased. The use of live vaccines should be avoided during treatment and for at least six months after treatment has finished and individual specialist advice sought.
4.5 Interaction with other medicinal products and other forms of interaction
The myelosuppressive activity may be potentiated by previous or concomitant radiotherapy or cytotoxic therapy. Fatal and non-fatal pancreatitis has occurred in HIV-infected patients during therapy with hydroxycarbamide and didanosine, with or without stavudine. Hepatotoxicity and hepatic failure resulting in death were reported during post-marketing surveillance in HIV-infected patients treated with hydroxycarbamide and other antiretroviral agents. Fatal hepatic events were reported most often in patients treated with the combination of hydroxycarbamide, didanosine and stavudine. This combination should be avoided. Peripheral neuropathy, which was severe in some cases, has been reported in HIV-infected patients receiving hydroxycarbamide in combination with antiretroviral agents, including didanosine, with or without stavudine.
Studies have shown that there is an analytical interference of hydroxycarbamide with the enzymes (urease, uricase, and lactic dehydrogenase) used in the determination of urea, uric acid and lactic acid, rendering falsely elevated results of these in patients treated with hydroxycarbamide.
There is an increased risk of severe or fatal infections with the concomitant use of live vaccines. Live vaccines are not recommended in immunosuppressed patients.
4.6 Fertility, pregnancy and lactation
Drugs which affect DNA synthesis, such as hydroxycarbamide, may be potent mutagenic agents. The physician should carefully consider this possibility before administering this drug to male or female patients who may contemplate conception. Since Hydroxyurea capsule is a cytotoxic agent it has produced a teratogenic effect in some animal species.
In rats and dogs, high doses of hydroxycarbamide reduced sperm production
Hydroxycarbamide is excreted in human breast milk. Because of the potential for serious adverse reactions in nursing infants from hydroxycarbamide, a decision should be made whether to discontinue nursing or to discontinue Hydroxyurea capsule, taking into account the importance of the drug to the mother.
Hydroxyurea capsule can cause fetal harm when administered to a pregnant woman. Hydroxyurea capsule should not normally be administered to patients who are pregnant, or to mothers who are breast feeding, unless the potential benefits outweigh the possible hazards.
When appropriate both male and female patients should be counselled concerning the use of contraceptive measures before and during treatment with Hydroxyurea capsule.
4.7 Effects on ability to drive and use machines
Hydroxycarbamide may cause drowsiness. Patients receiving it should not drive or operate machinery unless it has been shown not to affect physical or mental ability.
4.8 Undesirable effects
Bone-marrow suppression is the major toxic effect of hydroxycarbamide
Cutaneous vasculitic toxicities including vasculitic ulcerations and gangrene have occurred in patients with myeloproliferative disorders during therapy with hydroxycarbamide. The risk of vasculitic toxicities is increased in patients who receive prior or concomitant interferon therapy.
In some patients, hyperpigmentation, atrophy of skin and nails, scaling, violet papules and alopecia have been observed following several years of long-term daily maintenance therapy with hydroxycarbamide.
Cases of fatal and non-fatal pancreatitis and hepatotoxicity and severe peripheral neuropathy have been observed in HIV patients when hydroxycarbamide was administered with antiretroviral agents, in particular didanosine plus stavudine. Patients treated with hydroxycarbamide in combination with didanosine, stavudine and indinavir showed a median decline in CD4 cells of approximately 100/mm3.
Adverse reactions observed with combined Hydroxyurea capsule and irradiation therapy were similar to those reported with the use of Hydroxyurea capsule alone, primarily bone marrow depression (leukopenia and anaemia) and gastric irritation. Nearly all patients receiving an adequate course of combined Hydroxyurea capsule and irradiation therapy will develop leukopenia. Decreased platelet counts (<100,000/mm3) have occurred rarely and usually in the presence of marked leukopenia. Hydroxyurea capsule may potentiate some adverse reactions usually seen with irradiation alone, such as gastric distress and mucositis.
The list is presented by system organ class, MedDRA preferred term, and frequency using the following frequency categories: very common (?1/10), common (?1/100, < 1/10), uncommon (?1/1000, <1/100), rare (?1/10000, <1/1000), very rare (< 1/10000), and not known (cannot be estimated from the available data).
|System Organ Class||Frequency||MedDRA Term|
|Infections and Infestations||Rare||Gangrene|
|Neoplasms Benign and Malignant (including cysts and polyps)||Common||Skin cancer|
|Blood and Lymphatic System Disorders||Very common||Bone marrow failure, CD4 lymphocytes decreased, leukopenia, thrombocytopenia, platelet count decreased, anaemia|
|Metabolism and Nutrition Disorders||Very common||Anorexia|
|Psychiatric Disorders||Common||Hallucination, disorientation|
|Nervous System Disorders||Common||Convulsion, dizziness, peripheral neuropathy1, somnolence, headache|
|Respiratory, Thoracic, and Mediastinal Disorders||Common||Pulmonary fibrosis, pulmonary oedema, lung infiltration, dyspnoea|
|Gastrointestinal Disorders||Very common||Pancreatitis1, nausea, vomiting, diarrhoea, stomatitis, constipation, mucositis, stomach discomfort, dyspepsia, abdominal pain, melaena|
|Hepatobiliary Disorders||Common||Hepatotoxicity1, hepatic enzyme increased, cholestasis, hepatitis|
|Skin and Subcutaneous Tissue Disorders||Very common||Cutaneous vasculitis, dermatomyositis, alopecia, rash maculo-papular, rash papular, skin exfoliation, skin atrophy, skin ulcer, erythema, skin hyperpigmentation, nail disorder|
|Renal and Urinary Disorders||Very common||Dysuria, blood creatinine increased, blood urea increased, blood uric acid increased|
|General Disorders and Administration Site Conditions||Very common||Pyrexia, asthenia, chills, malaise|
|Reproductive system and breast disorders||Very common||azoospermia, oligospermia|
|1?Fatal and non-fatal pancreatitis and hepatotoxicity and severe peripheral neuropathy have been reported in HIV-infected patients who received hydroxyurea in combination with antiretroviral agents, in particular didanosine plus stavudine.|
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Immediate treatment consists of gastric lavage, followed by supportive therapy for the cardiorespiratory systems if required. In the long term, careful monitoring of the haemopoietic system is essential and, if necessary, blood should be transfused.
Acute mucocutaneous toxicity has been reported in patients receiving hydroxycarbamide at a dosage several times greater than that recommended. Soreness, violet erythema, oedema on palms and foot soles followed by scaling of hands and feet, intense generalised hyperpigmentation of skin, and severe acute stomatitis were observed.
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: other antineoplastic agents
Hydroxycarbamide is an orally active antineoplastic agent. Although the mechanism of action has not yet been clearly defined, hydroxycarbamide appears to act by interfering with synthesis of DNA.
5.2 Pharmacokinetic properties
After oral administration hydroxycarbamide is readily absorbed from the gastrointestinal tract. Peak plasma concentrations are reached in 2 hours; by 24 hours the serum concentrations are virtually zero. Approximately 80% of an oral or intravenous dose of 7 to 30 mg/kg may be recovered from the urine within 12 hours. Hydroxycarbamide crosses the blood-brain barrier. Hydroxycarbamide is well distributed throughout the body.
5.3 Preclinical safety data
Hydroxycarbamide is unequivocally genotoxic and a presumed transpecies carcinogen which implies a carcinogenic risk to humans.
6.1 List of excipients
Citric acid, anhydrous,
Gelatin capsules contain:
Yellow iron oxide,
6.3 Shelf life
6.4 Special precautions for storage
Do not store above 25?C. Store in the original package in order to protect from moisture.
6.5 Nature and contents of container
Carton containing 100 capsules in blisters consisting of PVC/PCTFE/PVC and sealed with aluminium foil with PVC/PVDC backing.
6.6 Special precautions for disposal and other handling
People who are not taking Hydroxyurea capsule should not be exposed to it. To decrease the risk of exposure, wear disposable gloves when handling Hydroxyurea capsule. Anyone handling Hydroxyurea capsule should wash their hands before and after contact with the capsules. If the powder is spilled, it should be immediately wiped with a damp disposable towel and discarded in a closed container, such as a plastic bag, as should the empty capsules. Hydroxyurea capsule should be kept away from children. Pregnant women should not handle Hydroxyurea capsule.
To minimise the risk of dermal exposure, always wear impervious gloves when handling capsules containing Hydroxyurea capsule. This includes all handling activities in clinical settings, pharmacies, storerooms and home healthcare settings, including during unpacking and inspection, transport within a facility, and dose preparation and administration. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
7. Manufactured in India By:
TAJ PHARMACEUTICALS LIMITED
at SURVEY NO.188/1 TO 189/1,190/1 TO 4,
DAMAN- 396210 (INDIA)
Hydroxyurea Capsule IP 500mg (Tharolax) Taj Pharma
Package leaflet: Information for the patient
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read itagain.
- If you have any further questions, ask your doctor orpharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harmthem, even if their signs of illness are the same asyours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section4.
What is in this leaflet:
- What Hydroxyurea is and what it is usedfor
- What you need to know before you take Hydroxyurea
- How to take Hydroxyurea
- Possible sideeffects
- How to store Hydroxyurea
- Contents of the pack and otherinformation
1 WHAT HYDROXYUREA IS AND WHAT IT IS USED FOR
The name of your medicine is Hydroxyurea. Each capsule contains hydroxycarbamide as the active ingredient. Hydroxycarbamide belongs to a group of medicines called anti-neoplastic medicines. These medicines interfere with the growth of cancer cells.
Hydroxyurea is used to treat some types of cancer such as cervical cancer and a type of leukaemia called chronic myeloid leukaemia (CML). The precise reason why you are being given Hydroxyurea is best discussed with your doctor. ?
2 WHAT YOU NEED TO KNOW BEFORE YOU TAKE HYDROXYUREA
Do not take Hydroxyurea Capsules:
? if you are allergic to hydroxycarbamide or any of the other ingredients of this medicine.
? if you have history of any blood problems
? if you have severe anaemia
Warnings and precautions
Talk to your doctor or pharmacist before taking Hydroxyurea.
Your doctor will do regular blood tests before and whilst you are taking Hydroxyurea. You may need to control or treat the source conditions before starting treatment with Hydroxyurea.
Take special care with Hydroxyurea Capsules if:
? you have any kidney or liver problems
? you are pregnant, planning to become pregnant or are breast feeding
? you have ever suffered from gout
? you have leg ulcers 2
? you have previously received radiotherapy or chemotherapy, or are currently taking any other medicines for cancer treatment, especially interferon therapy
? you have folic acid deficiency
In long term use of Hydroxyurea, secondary leukaemia has been reported. Skin cancer has also been reported in patient receiving long term hydroxycarbamide. You should protect your skin from the sun, regularly inspect your skin yourself and be screened by your doctor for secondary malignancies during routine follow-up visits.
Other medicines and Hydroxyurea
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, especially:
? Antiretroviral medicines (those that inhibit or destroy a retrovirus such as HIV), e.g., didanosine, stavudine and indinavir
? Myelosuppressive medicines (including chemotherapies) and radiation therapy
? Some vaccines, if you recently had a vaccination or are planning to have one, tell your doctor.
Always tell your doctor about other medicines you may be taking or have recently taken including those obtained without a prescription as some medicines can affect each others actions.
It may be necessary to adjust the dose of some medicines if they are taken at the same time as Hydroxyurea.
Hydroxyurea with food, drink or alcohol
You should check with your doctor before drinking alcohol to find out if it is advisable for you.
Pregnancy, breast-feeding and fertility
You should not take this medicine if you are pregnant, planning to become pregnant or are breastfeeding, unless your doctor recommends it. When appropriate both male and female patients should discuss safe contraceptive measure before and during treatment with Hydroxyurea. In addition, if you are pregnant, planning to be or breastfeeding you should not handle the capsules.
Driving and using machines
You may feel drowsy. You should not drive or operate any machinery unless it has been shown not to affect you and have discussed it with your doctor.
Hydroxyurea contains lactose
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
3 HOW TO TAKE HYDROXYUREA
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
You may be instructed to take your medicine on either a daily basis or an irregular basis.
The recommended dose is 20-30mg of Hydroxyurea per kg of your bodyweight once a day or 80 mg per kg of your body weight once every third day.
patients may be more sensitive to the effects of Hydroxyurea and may be given a lower dose.
You can take this medicine at any time of the day, before or after meals. The capsules should be swallowed whole with a glass of water. However if you find it difficult to swallow them, the contents of the capsule can be emptied into a glass of water and taken immediately. If some of the powder floats on the surface of the water, DO NOT WORRY this is just filler from the capsule. DO NOT inhale the contents of the capsules and if you spill any on the skin wipe it immediately.
While you are being treated with Hydroxyurea it is important that you drink plenty of fluids. This will help your kidneys work well.
If you are going to have radiation therapy, this medicine will usually be started 7 days before starting radiation treatment.
You should keep taking your capsules until your doctor tells you to stop.
Children There is limited experience with the use of Hydroxyurea in this age group
If you take more Hydroxyurea than you should
If you take too many capsules you should go to your nearest hospital Casualty Department immediately and take the medicine carton with you. The symptoms of overdose include; soreness, swelling of hands and feet and redness of skin.
If you forget to take
Hydroxyurea If you forget to take a dose of this medicine DO NOT take the missed dose at all. Take your next dose when it is due; DO NOT take a double dose to make up for a forgotten dose.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4 POSSIBLE SIDE EFFECTS
Like all medicines, this medicine can cause side effects, although not everybody gets them.
?If you notice any of the following symptoms swelling of the face, lips, tongue or throat, itching or skin rashes, difficulty breathing, unexplained fever, chills or sore throat, breathing difficulties, wasting of muscles and peeling of the skin and nails, you should stop taking the tablets and tell your doctor immediately as these may be signs of an allergic reaction:
If you notice any of these symptoms you should see your doctor immediately.
? unexplained shortness of breath or cough with fever, skin ulceration, especially with severe infection
? blood disorders (reduction in white blood cells, red blood cells and platelets)
? lower back pain or pain in your side
? black tarry stools or blood in the stools
? unusual bleeding or bruising
? numbness or tingling of hands or feet
The following side effects have been seen in some people:
? skin changes and muscle weakness (dermatomyositis) – you may experience symptoms such as muscle tenderness, muscle weakness or tiredness (especially when climbing stairs, 4 walking or rising from a chair etc), a rash on the face, hands or other parts of the body (which in some cases maybe scaly, purple and raised).
? absence or low amount of sperm in the semen (azoospermia or oligospermia).
? loss of appetite
? weakness, loss of energy
? sickness, diarrhoea, constipation, abdominal pain
? sores on the lips or mouth
? difficulty or pain passing urine
? skin problems may occur including rashes, darkening of the skin, peeling of the skin, purple raised patches of skin and redness. There may be a worsening of existing redness or discomfort in the skin or mucous membranes if you have had radiation treatment in the past.
? temporary hair loss
? kidney problems
? skin cancer
? problems with the flow of the bile (cholestasis), the bile which is made by the liver to aid in digestion of food may not flow properly. A build up of bile can cause itchiness, yellow skin, very dark urine and very pale stools ? inflammation of the liver (hepatitis) which cause flu-like symptoms, including tiredness, loss of appetite, fever, aching, and feeling sick/being sick, pressure or pain below the right ribs and might also include yellowing of the skin or eyes
? drowsiness, dizziness, fits, confusion or hallucinations (seeing hearing or feeling things that are not there)
Reporting of side effects
?If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.
5 HOW TO STOREHYDROXYUREA
Do not store your tablets above 25?C Store in the original package in order to protect from moisture.
Do not use this medicine after the expiry date which is stated on the blister or carton after EXP.
The expiry date refers to the last day of that month.
6 CONTENTS OF THE PACK AND OTHER INFORMATION
What Hydroxyurea contains
The active ingredient is hydroxycarbamide.
Each capsule contains:
Hydroxycarbamide IP?? 500mg
Lactose monohydrate?? 42.2mg???????????????
– The other ingredients are citric acid anhydrous, erythrosine, gelatin, indigotine, lactose monohydrate, magnesium stearate, sodium laurilsulfate, sodium phosphate, titanium dioxide, yellow iron oxide.
Contents of the pack
Hydroxyurea capsules are pink, opaque capsules with green, opaque caps. Hydroxyurea capsules are packed in blister packs of 100 capsules. People who are not taking Hydroxyurea should not be exposed to it. To decrease the risk of exposure, wear disposable gloves when handling Hydroxyurea. Anyone handling Hydroxyurea should wash their hands before and after contact with the capsules. Pregnant women should not handle Hydroxyurea.
7. Manufactured in India By:
TAJ PHARMACEUTICALS LIMITED
at SURVEY NO. 188/1, 190/1TO 4,
ATHIYAWAD , DABHEL,
DAMAN- 396210 (INDIA)